Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998446 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL13998326 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL8083544 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL29756403 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL8095380 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL343766 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL4160010 | 1.00 | PDE4A (0.58) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| Ammonia Solution, Strong SCHEMBL28915080 | 0.98 | PDE4A (0.56) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL15239580 | 0.93 | PDE4A (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 | |
| SCHEMBL13879019 | 0.93 | PDE4A (0.48) | PDE4ALMNAL3MBTL1TDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824434-A | A kind of selenium-enriched foliage fertilizer | 克拉玛依市三达农牧有限责任公司 | 2019-05-31 | — | — | CN | claimed |
| CN-109012132-A | A kind of composition of changeable colour and its preparation method and application decomposing low molecule aldehyde | 王中文 | 2018-12-18 | — | — | CN | claimed |
| CN-109824434-A | A kind of selenium-enriched foliage fertilizer | 克拉玛依市三达农牧有限责任公司 | 2019-05-31 | — | — | CN | disclosed |
| CN-109012132-A | A kind of composition of changeable colour and its preparation method and application decomposing low molecule aldehyde | 王中文 | 2018-12-18 | — | — | CN | disclosed |
| CN-109012132-A | A kind of composition of changeable colour and its preparation method and application decomposing low molecule aldehyde | 王中文 | 2018-12-18 | — | — | CN | disclosed |
| US-9809528-B2 | Production of alpha-hydroxy carboxylic acids and esters from higher sugars using tandem catalyst systems | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170015614-A1 | PRODUCTION OF ALPHA-HYDROXY CARBOXYLIC AIDS AND ESTERS FROM HIGHER SUGARS USING TANDEM CATALYST SYSTEMS | UNITED STATES DEPARTMENT OF ENERGY | 2017-01-19 | — | — | US | disclosed |
| US-20130059807-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130034536-A1 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120157399-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SATIOGEN PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157399-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | PDE4A 1107/4885LMNA 4642/4885L3MBTL1 4116/4885 |
| US-20130059807-A1 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SLC10A2, GPR119, GPBAR1 | PDE4A 2820/4885LMNA 4867/4885L3MBTL1 4791/4885 |
| US-20130034536-A1 | Bile Acid Recycling Inhibitors for Treatment of Pancreatitis | SLC10A2, SLC10A1, NR1H4 | PDE4A 453/4885LMNA 4841/4885L3MBTL1 4567/4885 |
| US-20100130472-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF OBESITY AND DIABETES | SLC10A1, SLC10A2, ABCB11 | PDE4A 1107/4885LMNA 4642/4885L3MBTL1 4116/4885 |
| US-20170015614-A1 | PRODUCTION OF ALPHA-HYDROXY CARBOXYLIC AIDS AND ESTERS FROM HIGHER SUGARS USING TANDEM CATALYST SYSTEMS | DERA, ALDOA, TKT | PDE4A 4744/4885LMNA 3773/4885L3MBTL1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.